Invizyne
eXoZymes is a Nasdaq-listed cell-free biomanufacturing platform company that uses AI-enhanced enzymes (exozymes) to produce complex molecules for pharmaceutical, wellness, fragrance, and cannabinoid applications without living cells.
- Company typePublic
- Founded2019
- HeadquartersMonrovia, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Invizyne firmographics
Firmographics- Name
- Invizyne
- Legal name
- eXoZymes Inc.
- Website
- https://invizyne.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- eXoZymes is a Nasdaq-listed cell-free biomanufacturing platform company that uses AI-enhanced enzymes (exozymes) to produce complex molecules for pharmaceutical, wellness, fragrance, and cannabinoid applications without living cells.
- Ownership category
- akta.pro rank
Where Invizyne is headquartered
LocationHeadquarters
- HQ city
- Monrovia
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Invizyne business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Product Sales - NCT: Sale of NCT (non-rare natural product) as metabolic wellness ingredient, addressing cellular energy efficiency through over-the-counter and pharmaceutical pathways
- Platform Licensing: Licensing of cell-free biomanufacturing platform technology to pharmaceutical and chemical manufacturing partners for production of proprietary compounds
- Grant Funding: Non-dilutive funding from government agencies (NIH, DOE, NSF) for specific research programs in cannabinoids, sustainable aviation fuel, and modular cell-free biomanufacturing
- Non-Intoxicating Cannabinoids: Production and commercialization of novel cannabinoid molecules for therapeutic applications, enabled by platform technology
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Invizyne product offering
Product offeringCore offering
eXoZymes develops and operates an AI-enhanced, cell-free biomanufacturing platform using proprietary exozymes to produce complex molecules such as NCT (a rare natural product for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The BioClick enzyme engineering platform supports the design and optimization of custom exozymes, while subsidiary NCTx commercializes NCT for gut and liver health. Revenue is generated through direct product sales, technology licensing, and government grants.
Product overview
eXoZymes offers an AI-enhanced, cell-free biomanufacturing platform that produces complex molecules through exozymes (AI-engineered enzymes operating outside living cells). The platform powers multiple products including NCT (for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The company has launched BioClick for enzyme engineering and spinout subsidiary NCTx for gut and liver health applications. The platform eliminates the scaling bottleneck of traditional synthetic biology by bypassing cellular limitations.
Differentiator
Problem solved
Functional benefit
Brands
- NCTx: Subsidiary focused on developing and commercializing NCT compound for gut and liver health.
Quantifiable outcome
- 100× scale-up of NCT production achieved with near-perfect feedstock conversion
- +2 more outcomes
Companies that use Invizyne
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
Invizyne technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
Invizyne partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- Lawrence Berkeley National Laboratory (LBNL)coreJoint award from DoE's Genesis Mission to advance AI-powered digital twins for cell-free biomanufacturing. Combines eXoZymes' platform with LBNL's computational capabilities for next-generation biomanufacturing modeling.
- Shell GameChanger Accelerator / NLRmajorGraduated from Shell GameChanger Accelerator Powered by NLR (GCxN) program. Program supports development of clean technology solutions with potential for sustainable aviation fuel and industrial chemical production.
- Cayman ChemicalcorePilot scale validation partnership with Cayman Chemical completed successfully. Tech transfer validated with pharma-grade output of NCT. Partnership enables commercial-scale production capability and provides third-party validation of platform technology.
- BioMADEmajoreXoZymes leaders (CCO Damien Perriman, VP Dr. Paul Opgenorth) join BioMADE Leadership & Technical Committees. BioMADE is a Manufacturing USA institute focused on bioindustrial manufacturing.
- META-PURE Consortium (NSF-funded)coreCore industry partner in $9M NSF-funded initiative to advance modular cell-free biomanufacturing. Collaboration with academic institutions and other industry partners to develop standardized cell-free production modules.
- U.S. Department of Energy (DOE) / BioMADEcore$2M project to advance sustainable aviation fuel capabilities through cell-free biomanufacturing. Collaboration between DOE and BioMADE.
Scale indicators9 records
Recent moves10 records
Expansion highlights6 records
Invizyne competitors and assessment
Company assessmentBroad incumbents
- Novonesis (formerly Novozymes): Novonesis is a global enzyme manufacturer producing enzymes for industrial applications across multiple sectors. Comparable to eXoZymes as an enzyme-focused company, though Novonesis operates at much larger scale with established commercial products.
- DSM-Firmenich: DSM-Firmenich produces specialty ingredients including flavors, fragrances, and nutritional products using biotechnology. Comparable to eXoZymes in producing high-value specialty molecules for fragrance and wellness markets.
Emerging players
- Twist Bioscience: Twist Bioscience provides synthetic biology tools including DNA synthesis and antibody discovery. Comparable to eXoZymes in offering synthetic biology platforms, though Twist focuses on DNA-based products rather than chemical manufacturing.
Direct peers
- Codexis: Codexis engineers enzymes for chemical and pharmaceutical manufacturing, including sustainable production routes. Closely comparable to eXoZymes' enzyme-engineering and cell-free biomanufacturing approach for specialty chemicals.
- Genomatica: Genomatica develops bio-based processes for producing widely-used chemicals from renewable feedstocks. Comparable to eXoZymes in using biological approaches to replace petrochemical production of specialty chemicals.
- Amyris: Amyris uses synthetic biology to produce specialty ingredients for fragrance, cosmetics, and flavors. Comparable to eXoZymes in targeting high-value specialty molecules via biological production, though Amyris uses cell-based fermentation.
- Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform for organism engineering across multiple industries. Both companies apply biology to produce specialty chemicals, making them direct competitors in the biomanufacturing space.
- LanzaTech: LanzaTech uses biological processes (gas fermentation) to produce sustainable fuels and chemicals from waste gases. Comparable to eXoZymes in applying biological conversion to produce specialty chemicals and sustainable fuels, including sustainable aviation fuel collaborations.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Invizyne social profiles
Digital presenceInvizyne financial estimates
Financial estimateRevenue estimate
Valuation estimate
Invizyne leadership team
Management profileNumber of profiles
Profiles7 records
Invizyne subsidiaries and ownership
Company hierarchySubsidiaries1 record
Invizyne funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Invizyne M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Invizyne
What does Invizyne do?
eXoZymes develops and operates an AI-enhanced, cell-free biomanufacturing platform using proprietary exozymes to produce complex molecules such as NCT (a rare natural product for metabolic wellness and pharmaceutical applications), non-intoxicating cannabinoids, and santalene fragrance compounds. The BioClick enzyme engineering platform supports the design and optimization of custom exozymes, while subsidiary NCTx commercializes NCT for gut and liver health. Revenue is generated through direct product sales, technology licensing, and government grants.
Is Invizyne a public or private company?
Invizyne is a public company. It is classified as public and is currently operating.
When was Invizyne founded?
Invizyne was founded in 2019. It employs 11 to 50 people.
Where is Invizyne based?
Invizyne is headquartered in Monrovia, United States, in the North America region.
How does Invizyne make money?
Four revenue lines are on record. Product Sales - NCT is the primary driver. The others are platform Licensing, grant Funding and non-Intoxicating Cannabinoids.
Who are Invizyne's main competitors?
Broad incumbents on record are Novonesis (formerly Novozymes) and DSM-Firmenich. Twist Bioscience is listed as an emerging player. Direct peers are Codexis, Genomatica, Amyris, Ginkgo Bioworks and LanzaTech.
Does Invizyne have an API?
No public API is recorded for Invizyne.